First Wave BioPharma, Inc. is a clinical stage biopharmaceutical company specializing in the development of targeted, orally delivered therapies for gastrointestinal (GI) diseases.

First Wave is currently advancing a therapeutic development pipeline populated with multiple clinical stage programs built around its three proprietary technologies – latiglutenase, a potentially first-in-class oral biotherapeutic designed to aid gluten digestion and potentially reduce symptoms of celiac disease; capeserod, a selective 5-HT4 receptor partial agonist being developed for gastroparesis; and the biologic adrulipase, a recombinant lipase designed to enable the digestion of fats and other nutrients in patients with exocrine pancreatic insufficiency.


logo ICO


777 Yamato Road
Suite 502
Boca Raton, FL 33431
(561) 589-7020